ZAZaida L. Almeida

Zaida L. Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zaida L. Almeida has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Influence of commensal bacteria on the proteolytic and antigenic profiles of INFOGEST-like digested wheat gliadin

    by Flávio Pereira-Costa, Vanessa S. Domingues, Ana Roque, Zaida L. Almeida, Pedro F. Cruz, Rachel Cordeiro, Daniela Trindade, Carla Moura, Joana B. Melo, Sónia G. Pereira, et al.

    Correction on: Pereira-Costa F, Domingues VS, Roque A, Almeida ZL, Cruz PF, Cordeiro R, Trindade D, Moura C, Melo JB, Pereira SG and Vaz DC (2026) Influence of commensal bacteria on the proteolytic and antigenic profiles of INFOGEST-like digested wheat gliadin. Front. Microbiol. 17:1842801. doi: 10.3389/fmicb.2026.1842801 In the Funding statement, the funder "2022 Beyond Celiac Established Investigator Award (BeyondCeliac.org)" was omitted. The correct Funding statement reads:"The author(s) declared that financial support was received for this work and/or its publication.

  • Open Access

    Influence of commensal bacteria on the proteolytic and antigenic profiles of INFOGEST-like digested wheat gliadin

    by Flávio Pereira-Costa, Vanessa S. Domingues, Ana Roque, Zaida L. Almeida, Pedro F. Cruz, Rachel Cordeiro, Daniela Trindade, Carla Moura, Joana B. Melo, Sónia G. Pereira, et al.

    Introduction: Celiac disease (CeD) is a chronic autoimmune enteropathy developed by genetically predisposed individuals when exposed to gluten. Gluten gliadins, along with gut microbiota, may influence CeD onset and progression through mechanisms that remain unclear. Methods: Gliadin-degrading bacterial isolates obtained from CeD patients, and their 1st-degree relatives’ stool and blood were identified ( Bacillus tropicus , Enterococcus faecalis , Micrococcus sp., Cronobacter sakazakii , Pseudomonas aeruginosa , and Serratia marcescens ) and used in an INFOGEST-like protocol to simulate gliadin digestion after 4 h (digested gliadin, d-gliadin). The d-gliadin digesta were analyzed by fast protein liquid chromatography (FPLC), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), fluorescence spectroscopy, and polyclonal and monoclonal (R5 and G12) enzyme-linked immunosorbent assays (ELISA). Results and discussion: In the absence of the bacterial isolates, gliadin is poorly digested and self-assembles within 1 day into intermediate and large protein oligomers/aggregates, enriched in β-sheet structure (FTIR amide I band between 1,600 and 1,700 cm −1 ) and able to bind thioflavin T and Congo red. Conversely, in the presence of the bacterial isolates, gliadin is further digested, leading to an increase in protein fragments. After 4 h, the P. aeruginosa , C. sakazakii , and B. tropicus d-gliadin digesta presented a mixture of d-gliadin peptides and aggregates that showed higher antigenicity (associated with the exposure of the 5-amino acid QQPFP and 6-amino acid QPQLPY epitopes, present in the 25-mer and 33-mer, respectively) than control digestions (without bacteria), while E. faecalis led to lower antigenicity. In turn, within 24 h of incubation, all bacterial isolates led to the formation of undigested material with lower antigenicity, either due to fewer 33-mers and 25-mers in solution, or to fragment aggregation into amorphous material, not exposing antigenic sequences. Hence, intestinal flora may enhance or diminish the antigenicity of gliadin, thereby modulating the immunogenic response to gliadin/gluten.

  • Formulation of Bread with Portuguese Ancient Wheat from Sourdough Fermentation: Nutritional Composition, Physicochemical Properties and Impact on Glycaemia

    by Joana A. Branco, Diana P. Silva, Beatriz A. Silva, Carla Guimarães, Daniela Vaz, Zaida L. Almeida, Cidália D. Pereira, Vânia S. Ribeiro

  • Open Access

    Optimized ultrasound-assisted extraction of betulin from Betula pendula bark: a sustainable approach to forest residue valorization

    by Nuria Chinchilla, Bruno Medronho, Zaida L. Almeida, María José Aliaño-González, Francisco A. Macías, Miguel Palma, Anabela Romano, Ida Svanedal, Magnus Norgren, Ceferino Carrera

    The outer bark of Betula pendula (silver birch), a lignocellulosic byproduct of wood processing, offers valuable opportunities for the recovery of high-value bioactive compounds. betulin, a triterpenoid responsible for the white coloration of silver birch bark, has attracted considerable attention due to its pharmacological properties, including antioxidant, anti-inflammatory, and anticancer effects. In this study, a green ultrasound-assisted extraction (UAE) method was developed and optimized for the selective extraction of betulin from Betula pendula outer bark. In order to evaluate the effects of ethanol concentration, temperature, sonication amplitude, and cycle on betulin yield, a Box–Behnken design was employed in combination with response surface methodology. Optimal conditions were identified at 92% ethanol, 57 °C, 70% amplitude, and 0.3 Hz − 1 cycle for 15 min of extraction. The process demonstrated excellent repeatability (C.V. < 5%). A positive correlation was identified between betulin concentration and antioxidant capacity, thereby confirming the efficacy of the employed methodology. This work constitutes a significant UAE protocol for B. pendula outer bark, delivering 34.63 mg·g − 1 betulin and outperforming conventional techniques in terms of time and solvent usage, thus contributing to the development of circular biorefinery approaches within the wood industry.


  • Open Access

    Serum-PEG and BSA-PEG hydrogels as advanced platforms for evaluating plasma protein binding

    by Carlos D.F. Coelho, Victor S. Paiva, Zaida L. Almeida, João A. Jesus, Madalena Marteleira, Cristiana V. Ramos, Pedro F. Cruz, Telma Costa, Carla S. Moura, Daniela Trindade, et al.


  • Open Access

    Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis

    by Zaida L. Almeida, Daniela C. Vaz, Rui M. M. Brito

    Alzheimer’s disease (AD) is the most common form of dementia around the world (~ 65%). Here, we portray the neuropathology of AD, biomarkers, and classification of amyloid plaques (diffuse, non-cored, dense core, compact). Tau pathology and its involvement with Aβ plaques and cell death are discussed. Amyloid cascade hypotheses, aggregation mechanisms, and molecular species formed in vitro and in vivo (on- and off-pathways) are described. Aβ42/Aβ40 monomers, dimers, trimers, Aβ‐derived diffusible ligands, globulomers, dodecamers, amylospheroids, amorphous aggregates, protofibrils, fibrils, and plaques are characterized (structure, size, morphology, solubility, toxicity, mechanistic steps). An update on AD-approved drugs by regulatory agencies, along with new Aβ-based therapies, is presented. Beyond prescribing Aβ plaque disruptors, cholinergic agonists, or NMDA receptor antagonists, other therapeutic strategies (RNAi, glutaminyl cyclase inhibitors, monoclonal antibodies, secretase modulators, Aβ aggregation inhibitors, and anti-amyloid vaccines) are already under clinical trials. New drug discovery approaches based on “designed multiple ligands”, “hybrid molecules”, or “multitarget-directed ligands” are also being put forward and may contribute to tackling this highly debilitating and fatal form of human dementia.


  • Open Access

    Revisiting and Updating the Interaction between Human Serum Albumin and the Non-Steroidal Anti-Inflammatory Drugs Ketoprofen and Ketorolac

    by Rita S. Cunha, Pedro F. Cruz, Telma Costa, Zaida L. Almeida, Marco Edilson Freire de Lima, Carlos Serpa, Otávio A. Chaves

    Ketoprofen (KTF) and ketorolac (KTL) are among the most primarily used non-steroidal anti-inflammatory drugs (NSAIDs) in humans to alleviate moderate pain and to treat inflammation. Their binding affinity with albumin (the main globular protein responsible for the biodistribution of drugs in the bloodstream) was previously determined by spectroscopy without considering some conventional pitfalls. Thus, the present work updates the biophysical characterization of the interactions of HSA:KTF and HSA:KTL by 1H saturation-transfer difference nuclear magnetic resonance (1H STD-NMR), ultraviolet (UV) absorption, circular dichroism (CD), steady-state, and time-resolved fluorescence spectroscopies combined with in silico calculations. The binding of HSA:NSAIDs is spontaneous, endothermic, and entropically driven, leading to a conformational rearrangement of HSA with a slight decrease in the α-helix content (7.1% to 7.6%). The predominance of the static quenching mechanism (ground-state association) was identified. Thus, both Stern–Volmer quenching constant (KSV) and binding constant (Kb) values enabled the determination of the binding affinity. In this sense, the KSV and Kb values were found in the order of 104 M−1 at human body temperature, indicating moderate binding affinity with differences in the range of 0.7- and 3.4-fold between KTF and KTL, which agree with the previously reported experimental pharmacokinetic profile. According to 1H STD-NMR data combined with in silico calculations, the aromatic groups in relation to the aliphatic moiety of the drugs interact preferentially with HSA into subdomain IIIA (site II) and are stabilized by interactions via hydrogen bonding and hydrophobic forces. In general, the data obtained in this study have been revised and updated in comparison to those previously reported by other authors who did not account for inner filter corrections, spectral backgrounds, or the identification of the primary mathematical approach for determining the binding affinity of HSA:KTF and HSA:KTL.


  • Open Access

    Transthyretin mutagenesis: impact on amyloidogenesis and disease

    by Zaida L. Almeida, Daniela C. Vaz, Rui M. M. Brito

    1. Protein aggregation and amyloid formation contribute to several debilitating diseases collectively known as Amyloidosis [1]. To date, more than fifty amyloid diseases have been identified, inclu...


  • Open Access

    Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors

    by Andreia Costa-Tuna, Otávio A. Chaves, Zaida L. Almeida, Rita S. Cunha, João Pina, Carlos Serpa

    Tenofovir (TFV) is the active form of the prodrugs tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both clinically prescribed as HIV reverse transcriptase inhibitors. The biophysical interactions between these compounds and human serum albumin (HSA), the primary carrier of exogenous compounds in the human bloodstream, have not yet been thoroughly characterized. Thus, the present study reports the interaction profile between HSA and TFV, TDF, and TAF via UV–Vis, steady-state, and time-resolved fluorescence techniques combined with isothermal titration calorimetry (ITC) and in silico calculations. A spontaneous interaction in the ground state, which does not perturb the microenvironment close to the Trp-214 residue, is classified as weak. In the case of HSA/TFV and HSA/TDF, the binding is both enthalpically and entropically driven, while for HSA/TAF, the binding is only entropically dominated. The binding constant (Ka) and thermodynamic parameters obtained via ITC assays agree with those obtained using steady-state fluorescence quenching measurements, reinforcing the reliability of the data. The small internal cavity known as site I is probably the main binding pocket for TFV due to the low steric volume of the drug. In contrast, most external sites (II and III) can better accommodate TAF due to the high steric volume of this prodrug. The cross-docking approach corroborated experimental drug-displacement assays, indicating that the binding affinity of TFV and TAF might be impacted by the presence of different compounds bound to albumin. Overall, the weak binding capacity of albumin to TFV, TDF, and TAF is one of the main factors for the low residence time of these antiretrovirals in the human bloodstream; however, positive cooperativity for TAF and TDF was detected in the presence of some drugs, which might improve their residence time (pharmacokinetic profile).


  • Open Access

    Amyloid Disassembly: What Can We Learn from Chaperones?

    by Zaida L. Almeida, Rui M. M. Brito

    Protein aggregation and subsequent accumulation of insoluble amyloid fibrils with cross-β structure is an intrinsic characteristic of amyloid diseases, i.e., amyloidoses. Amyloid formation involves a series of on-pathway and off-pathway protein aggregation events, leading to mature insoluble fibrils that eventually accumulate in multiple tissues. In this cascade of events, soluble oligomeric species are formed, which are among the most cytotoxic molecular entities along the amyloid cascade. The direct or indirect action of these amyloid soluble oligomers and amyloid protofibrils and fibrils in several tissues and organs lead to cell death in some cases and organ disfunction in general. There are dozens of different proteins and peptides causing multiple amyloid pathologies, chief among them Alzheimer’s, Parkinson’s, Huntington’s, and several other neurodegenerative diseases. Amyloid fibril disassembly is among the disease-modifying therapeutic strategies being pursued to overcome amyloid pathologies. The clearance of preformed amyloids and consequently the arresting of the progression of organ deterioration may increase patient survival and quality of life. In this review, we compiled from the literature many examples of chemical and biochemical agents able to disaggregate preformed amyloids, which have been classified as molecular chaperones, chemical chaperones, and pharmacological chaperones. We focused on their mode of action, chemical structure, interactions with the fibrillar structures, morphology and toxicity of the disaggregation products, and the potential use of disaggregation agents as a treatment option in amyloidosis.